Phase 3b results show risankizumab is superior for endoscopic remission and clinical remission at week 48 compared with ustekinumab, a "once in a career" result, study authors say.
Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib